Variable | Non-Survival (n = 124) | Survival (n = 386) | P value |
---|---|---|---|
Age (year) | 57.08 ± 13.05 | 59.67 ± 11.71 | 0.038 |
Gender (male, %) | 98, 79.03% | 239, 61.92% | < 0.001 |
Weight (kg) | 66.96 ± 11.89 | 62.81 ± 11.85 | 0.001 |
NYHA class (n, %) | 0.001 | ||
I | 5, 4.04% | 9, 2.33% | |
II | 55, 44.35% | 109, 28.24% | |
III | 55, 44.35% | 228, 59.07% | |
IV | 9, 7.26% | 40, 10.36% | |
EuroSCORE | 6.06 ± 2.45 | 4.54 ± 2.08 | < 0.001 |
Echocardiogram variables | |||
Preoperative LVEF (%) | 30.36 ± 4.29 | 30.99 ± 3.87 | 0.124 |
Preoperative LVDd (cm) | 7.11 ± 1.09 | 6.98 ± 1.05 | 0.258 |
Evaluated PAP (mmHg) | 47.85 ± 18.11 | 48.24 ± 13.66 | 0.817 |
Previous Medical History (n,%) | |||
Acute Myocardial infarction | 62, 50% | 56, 14.51% | < 0.001 |
Atrial fibrillation | 23, 18.55% | 101, 26.17% | 0.085 |
Diabetes Mellitus | 15, 12.10% | 34, 8.81% | 0.280 |
Chronic Renal Failure | 3, 2.42% | 6, 1.55% | 0.525 |
Hypertension | 33, 26.61% | 94, 24.35% | 0.613 |
Liver Disease | 4, 3.23% | 14, 3.63% | 0.833 |
COPD | 12, 9.68% | 8, 2.07% | < 0.001 |
Cancer | 2, 1.61% | 4, 1.04% | 0.604 |
Smoking | 42, 33.87% | 57, 14.77% | < 0.001 |
Excessive alcohol | 16, 12.90% | 28, 7.25% | 0.051 |
ACEI/ARB use | 2, 1.61% | 14, 3.63% | 0.258 |
Ca2+-Blocker use | 7, 5.64% | 11, 2.85% | 0.145 |
β-blocker use | 0 | 7, 1.81% | 0.130 |
Statin use | 3, 2.42% | 8, 2.07% | 0.798 |
Diuretic use | 9 | 25, 6.48% | 0.799 |
Aspirin use | 0 | 0 | – |
Clopidogrel use | 0 | 7, 1.81% | 0.130 |
Levosimendan use | 0 | 0 | – |
Lyophilized Recombinant Human Brain Natriuretic | 0 | 0 | – |